272 related articles for article (PubMed ID: 29941589)
1. Structure of the Lassa virus glycan shield provides a model for immunological resistance.
Watanabe Y; Raghwani J; Allen JD; Seabright GE; Li S; Moser F; Huiskonen JT; Strecker T; Bowden TA; Crispin M
Proc Natl Acad Sci U S A; 2018 Jul; 115(28):7320-7325. PubMed ID: 29941589
[TBL] [Abstract][Full Text] [Related]
2. Small-Molecule Fusion Inhibitors Bind the pH-Sensing Stable Signal Peptide-GP2 Subunit Interface of the Lassa Virus Envelope Glycoprotein.
Shankar S; Whitby LR; Casquilho-Gray HE; York J; Boger DL; Nunberg JH
J Virol; 2016 Aug; 90(15):6799-807. PubMed ID: 27194767
[TBL] [Abstract][Full Text] [Related]
3. Differential Antibody-Based Immune Response against Isolated GP1 Receptor-Binding Domains from Lassa and Junín Viruses.
Borenstein-Katz A; Shulman A; Hamawi H; Leitner O; Diskin R
J Virol; 2019 Apr; 93(8):. PubMed ID: 30728269
[TBL] [Abstract][Full Text] [Related]
4. Uncoupling GP1 and GP2 expression in the Lassa virus glycoprotein complex: implications for GP1 ectodomain shedding.
Illick MM; Branco LM; Fair JN; Illick KA; Matschiner A; Schoepp R; Garry RF; Guttieri MC
Virol J; 2008 Dec; 5():161. PubMed ID: 19105844
[TBL] [Abstract][Full Text] [Related]
5. Lassa virus glycoprotein: stopping a moving target.
Hastie KM; Saphire EO
Curr Opin Virol; 2018 Aug; 31():52-58. PubMed ID: 29843991
[TBL] [Abstract][Full Text] [Related]
6. Structural basis for antibody-mediated neutralization of Lassa virus.
Hastie KM; Zandonatti MA; Kleinfelter LM; Heinrich ML; Rowland MM; Chandran K; Branco LM; Robinson JE; Garry RF; Saphire EO
Science; 2017 Jun; 356(6341):923-928. PubMed ID: 28572385
[TBL] [Abstract][Full Text] [Related]
7. Old and New World arenaviruses share a highly conserved epitope in the fusion domain of the glycoprotein 2, which is recognized by Lassa virus-specific human CD4+ T-cell clones.
Meulen Jt; Badusche M; Satoguina J; Strecker T; Lenz O; Loeliger C; Sakho M; Koulemou K; Koivogui L; Hoerauf A
Virology; 2004 Mar; 321(1):134-43. PubMed ID: 15033572
[TBL] [Abstract][Full Text] [Related]
8. Molecular Mechanism for LAMP1 Recognition by Lassa Virus.
Cohen-Dvashi H; Cohen N; Israeli H; Diskin R
J Virol; 2015 Aug; 89(15):7584-92. PubMed ID: 25972533
[TBL] [Abstract][Full Text] [Related]
9. Shedding of soluble glycoprotein 1 detected during acute Lassa virus infection in human subjects.
Branco LM; Grove JN; Moses LM; Goba A; Fullah M; Momoh M; Schoepp RJ; Bausch DG; Garry RF
Virol J; 2010 Nov; 7():306. PubMed ID: 21062490
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the Lassa virus GP1 ectodomain shedding: implications for improved diagnostic platforms.
Branco LM; Garry RF
Virol J; 2009 Sep; 6():147. PubMed ID: 19778448
[TBL] [Abstract][Full Text] [Related]
11. Effects of N-Linked Glycan on Lassa Virus Envelope Glycoprotein Cleavage, Infectivity, and Immune Response.
Zhu X; Liu Y; Guo J; Cao J; Wang Z; Xiao G; Wang W
Virol Sin; 2021 Aug; 36(4):774-783. PubMed ID: 33689141
[TBL] [Abstract][Full Text] [Related]
12. Deletion of the first glycosylation site promotes Lassa virus glycoprotein-mediated membrane fusion.
Dong S; Mao W; Liu Y; Jia X; Zhang Y; Zhou M; Hou Y; Xiao G; Wang W
Virol Sin; 2023 Jun; 38(3):380-386. PubMed ID: 37059226
[TBL] [Abstract][Full Text] [Related]
13. Lassa virus glycoprotein complex review: insights into its unique fusion machinery.
Pennington HN; Lee J
Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35088070
[TBL] [Abstract][Full Text] [Related]
14. Convergent Structures Illuminate Features for Germline Antibody Binding and Pan-Lassa Virus Neutralization.
Hastie KM; Cross RW; Harkins SS; Zandonatti MA; Koval AP; Heinrich ML; Rowland MM; Robinson JE; Geisbert TW; Garry RF; Branco LM; Saphire EO
Cell; 2019 Aug; 178(4):1004-1015.e14. PubMed ID: 31398326
[TBL] [Abstract][Full Text] [Related]
15. Acidic pH-Induced Conformations and LAMP1 Binding of the Lassa Virus Glycoprotein Spike.
Li S; Sun Z; Pryce R; Parsy ML; Fehling SK; Schlie K; Siebert CA; Garten W; Bowden TA; Strecker T; Huiskonen JT
PLoS Pathog; 2016 Feb; 12(2):e1005418. PubMed ID: 26849049
[TBL] [Abstract][Full Text] [Related]
16. Lassa virus glycoprotein nanoparticles elicit neutralizing antibody responses and protection.
Brouwer PJM; Antanasijevic A; Ronk AJ; Müller-Kräuter H; Watanabe Y; Claireaux M; Perrett HR; Bijl TPL; Grobben M; Umotoy JC; Schriek AI; Burger JA; Tejjani K; Lloyd NM; Steijaert TH; van Haaren MM; Sliepen K; de Taeye SW; van Gils MJ; Crispin M; Strecker T; Bukreyev A; Ward AB; Sanders RW
Cell Host Microbe; 2022 Dec; 30(12):1759-1772.e12. PubMed ID: 36400021
[TBL] [Abstract][Full Text] [Related]
17. The antifungal isavuconazole inhibits the entry of lassa virus by targeting the stable signal peptide-GP2 subunit interface of lassa virus glycoprotein.
Zhang X; Tang K; Guo Y
Antiviral Res; 2020 Feb; 174():104701. PubMed ID: 31877348
[TBL] [Abstract][Full Text] [Related]
18. Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens.
Doores KJ; Bonomelli C; Harvey DJ; Vasiljevic S; Dwek RA; Burton DR; Crispin M; Scanlan CN
Proc Natl Acad Sci U S A; 2010 Aug; 107(31):13800-5. PubMed ID: 20643940
[TBL] [Abstract][Full Text] [Related]
19. Mutational Analysis of Lassa Virus Glycoprotein Highlights Regions Required for Alpha-Dystroglycan Utilization.
Acciani M; Alston JT; Zhao G; Reynolds H; Ali AM; Xu B; Brindley MA
J Virol; 2017 Sep; 91(18):. PubMed ID: 28679759
[TBL] [Abstract][Full Text] [Related]
20. Structure-Based Classification Defines the Discrete Conformational Classes Adopted by the Arenaviral GP1.
Pryce R; Ng WM; Zeltina A; Watanabe Y; El Omari K; Wagner A; Bowden TA
J Virol; 2019 Jan; 93(1):. PubMed ID: 30305351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
